Compare GSK plc (GSK) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard S&P 500 ETF — how do they compare? GSK plc trades at $52.39 (market cap $101.34B), while Vanguard S&P 500 ETF trades at $693.4. The key difference: GSK plc pays a 3.49% dividend while Vanguard S&P 500 ETF pays none, and Vanguard S&P 500 ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | VOO | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $698.29 |
52-Week Low | $36.20 | $571.45 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
VOO trades at $692.99, up 0.27% with a bullish technical signal from moving averages. The ETF tracks the S&P 500, providing diversified exposure to large-cap US stocks. Recent news highlights strong investor interest in passive index strategies, with multiple articles recommending Vanguard ETFs for long-term wealth building. Technical indicators show support at $691 and resistance at $696, with the current price near the pivot point of $693.
VOO offers broad market exposure with low expense ratios, making it suitable for core portfolio holdings. The primary risk remains overall market volatility, as the fund's performance correlates directly with the S&P 500. Current sentiment is positive given the bullish technical outlook and ongoing institutional support for passive investing strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
